Lexeo therapeutics, inc. common stockLXEO.US Overview
LXEO Overall Performance
LXEO AI Analysis & Strategy
LXEO Recent Performance
-1.09%
Lexeo therapeutics, inc. common stock
0.81%
Avg of Sector
-1.14%
S&P500
LXEO PowerScanner
LXEO Key Information
LXEO Valuation Metrics
LXEO Earnings Table
LXEO Profile
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.